Streetbeat News

MYNZ

Mainz Biomed B.V.

https://mainzbiomed.com

Industry

Medical - Diagnostics & Research

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Open

0.25

Mkt cap

5.2M

Volume

2.6M

High

0.25

P/E Ratio

-0.22

52-wk high

1.79

Low

0.23

Div yield

N/A

52-wk low

0.18

Pfizer presented positive trial data for its experimental drug ponsegromab, aimed at treating cancer cachexia, at the European Society for Medical Oncology 2024 Congress. The drug showed promising results in improving weight and quality of life for patients. Pfizer plans to start late-stage trials in 2025. Moderna and Merck are also advancing in cancer treatment with their experimental cancer vaccine and immunotherapy drug. Mainz Biomed is working on early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

September 20, 2024 | 2:48 pm

Mainz Biomed has expanded its collaboration with Liquid Biosciences to enhance its pancreatic cancer detection test using AI technology. The partnership aims to optimize biomarker selection for the PancAlert test, with promising initial results. The next phase will include microbiome biomarkers and an extended AI algorithm, expected to complete by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 8:06 am

Pfizer has recorded its first sales growth in the post-COVID era, driven by cancer and heart drugs. Smaller players like Mainz Biomed are also making strides in oncology. Pfizer's Q2 revenue grew 3% YoY to $13.28 billion, with significant contributions from cancer therapies and heart disease drugs. Merck also exceeded estimates, driven by its cancer drug Keytruda. Pfizer raised its full-year outlook, expecting earnings per share between $2.45 and $2.65.

Portfolio Pulse from Upwallstreet

July 30, 2024 | 4:09 pm

Mainz Biomed has announced improvements to its ColoAlert product, which is designed for colorectal cancer screening. The enhancements aim to increase the test's accuracy and ease of use.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:11 pm

mRNA technology is making significant strides in cancer treatment, with Moderna and Merck collaborating on an experimental mRNA vaccine combined with Keytruda showing promising results in melanoma treatment. Mainz Biomed is also advancing early cancer diagnostics with its ColoAlert test, showing high sensitivity in detecting colorectal cancer and precancerous lesions.

Portfolio Pulse from Upwallstreet

July 02, 2024 | 5:38 pm

Mainz Biomed has achieved significant milestones in the first half of 2024, including presenting leading study results, securing strategic partnerships, and preparing for FDA pre-market approval and a U.S. go-to-market strategy for its ColoAlert product.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:08 pm

Merck Group ends Phase III trial of cancer drug Xevinapant, while Merck & Co reports positive data for its antibody-drug conjugate therapy and continues trials with Moderna for a melanoma vaccine. Mainz Biomed presents promising results for its colorectal cancer test and prepares for FDA approval.

Portfolio Pulse from Upwallstreet

June 26, 2024 | 3:29 pm

Promising trial results from Pfizer, Moderna, Merck, and Mainz Biomed indicate potential new standards in cancer treatment and diagnostics. Pfizer's Lorbrena shows significant long-term benefits for lung cancer patients, while Moderna and Merck's combined melanoma treatment demonstrates durable efficacy. Mainz Biomed's ColoAlert® test for colorectal cancer also shows high sensitivity and specificity.

Portfolio Pulse from Upwallstreet

June 04, 2024 | 5:45 pm

The article highlights the pre-market movements of 12 healthcare stocks on Tuesday. Annexon (ANNX) saw the highest gain with a 57.2% increase, while Bio-Path Holdings (BPTH) experienced the largest decline, dropping by 24.1%.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:06 pm

Mainz Biomed presented new study data at the ASCO 2024 Annual Meeting, confirming the high sensitivity of its mRNA biomarkers for detecting colorectal cancer (CRC) and advanced adenomas. The results showed 92% sensitivity for CRC and 82% for advanced adenomas, with 95.8% detection of high-grade dysplasia.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.